Search research articles
Contact Us
Filters
Showing results (81-90 of 300) with videos related to
Page
of 30
Sort By:
Clinical Drug Investigation
|
September 12, 2008
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet
Michael H Davidson, Peter H Jones
Reviews in Cardiovascular Medicine
|
July 14, 2009
Updating the assessment of cardiac risk: beyond Framingham
William B Borden, Michael H Davidson
Current Treatment Options in Cardiovascular Medicine
|
November 14, 2013
Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes
Michael J Wilkinson, Michael H Davidson
Journal of the National Cancer Institute
|
April 2, 2014
RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial
William S Harris, Michael H Davidson
Metabolic Syndrome and Related Disorders
|
March 29, 2008
New concepts in dyslipidemia in the metabolic syndrome and diabetes
Michael H Davidson, H Daniel Yannicelli
Journal of Clinical Lipidology
|
December 3, 2010
High-density lipoproteins: marker of cardiovascular risk and therapeutic target
Peter P Toth, Michael H Davidson
Current Atherosclerosis Reports
|
February 4, 2003
Efficacy of over-the-counter nutritional supplements
Michael H Davidson, Chris T Geohas
Expert Opinion on Pharmacotherapy
|
February 16, 2005
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
Peter P Toth, Michael H Davidson
The American Journal of Cardiology
|
December 28, 2004
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Peter H Jones, Michael H Davidson
Trends in Cardiovascular Medicine
|
August 29, 2020
Recent advances and emerging therapies in management of dyslipidemias
Vishnu Priya Pulipati, Michael H Davidson
Page
of 30
Search research articles
Search
Showing results (81-90 of 300) with videos related to
Sort By:
Page
of 30
Clinical Drug Investigation
|
September 12, 2008
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet
Michael H Davidson, Peter H Jones
Reviews in Cardiovascular Medicine
|
July 14, 2009
Updating the assessment of cardiac risk: beyond Framingham
William B Borden, Michael H Davidson
Current Treatment Options in Cardiovascular Medicine
|
November 14, 2013
Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes
Michael J Wilkinson, Michael H Davidson
Journal of the National Cancer Institute
|
April 2, 2014
RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial
William S Harris, Michael H Davidson
Metabolic Syndrome and Related Disorders
|
March 29, 2008
New concepts in dyslipidemia in the metabolic syndrome and diabetes
Michael H Davidson, H Daniel Yannicelli
Journal of Clinical Lipidology
|
December 3, 2010
High-density lipoproteins: marker of cardiovascular risk and therapeutic target
Peter P Toth, Michael H Davidson
Current Atherosclerosis Reports
|
February 4, 2003
Efficacy of over-the-counter nutritional supplements
Michael H Davidson, Chris T Geohas
Expert Opinion on Pharmacotherapy
|
February 16, 2005
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
Peter P Toth, Michael H Davidson
The American Journal of Cardiology
|
December 28, 2004
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Peter H Jones, Michael H Davidson
Trends in Cardiovascular Medicine
|
August 29, 2020
Recent advances and emerging therapies in management of dyslipidemias
Vishnu Priya Pulipati, Michael H Davidson
Page
of 30